Answers are grounded in this paper and cite their sources.
Maintaining target glycated hemoglobin levels is a primary objective in the management of patients with type 1 and type 2 diabetes mellitus (T1DM and T2DM), aimed at reducing the risk of severe vascular complications. Self-monitoring of blood glucose serves as the foundation for making therapeutic decisions and increasing patient engagement in the treatment process. Despite the widespread adoption of continuous glucose monitoring systems, traditional capillary blood glucose monitoring remains the dominant method for millions of people worldwide (particularly for patients with T2DM not requiring insulin therapy, in resource-limited settings, and as a necessary step for verifying continuous monitoring readings). The current stage of technological development is characterized by a shift from standalone devices to integrated digital tools. Wireless data transmission and automated trend analysis are emerging as distinct and clinically significant aspects of monitoring. Consequently, evaluating the efficacy of modern "connected" systems – which combine analytical accuracy with digital support tools – is of great importance. Current clinical guidelines recommend that the choice of device be individualized, based on the treatment regimen, cost, and patient preferences.
No takes yet. Share an insight, caveat, or question.
Pigarova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: